Recombinant Erdr1 suppresses the migration and invasion ability of human gastric cancer cells, SNU-216, through the JNK pathway

Immunology Letters

Volumn 150, Issue 1-2, 2013, Pages 145-151

  Jung, Min Kyung ^a   Houh, Youn Kyung ^b   Ha, Soogyeong ^a   Yang, Yoolhee ^c   Kim, Daejin ^d   Kim, Tae Sung ^e   Yoon, Suk Ran ^f   Bang, Sa Ik ^c   Cho, Byung Joo ^g   Lee, Wang Jae ^h   Park, Hyunjeong ⁱ   Cho, Daeho ^a  

^a Sookmyung Women's University   (South Korea)

^b Konkuk University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Korea University   (South Korea)

^f Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^g Konkuk University Hospital   (South Korea)

^h Seoul National University College of Medicine   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

Author keywords

E cadherin; Erdr1; Erythroid differentiation regulator 1; Gastric cancer; Invasion; JNK; Migration

Indexed keywords

ACTIVIN A; ANTIMETASTATIC AGENT; ERYTHROID DIFFERENTIATION FACTOR 1; INTERLEUKIN 18; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RECOMBINANT ERYTHROID DIFFERENTIATION FACTOR 1; RECOMBINANT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; METASTASIS INHIBITION; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; UPREGULATION;

CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; INTERLEUKIN-18; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84874405010     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.01.012     Document Type: Article

References (43)

1. Setiawan V.W., Zhang Z.F., Yu G.P., Li Y.L., Lu M.L., Tsai C.J., et al. GSTT1 and GSTM1 null genotypes and the risk of gastric cancer: a case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev 2000, 9:73-80.
2. Blaser M.J., Perez-Perez G.I., Kleanthous H., Cover T.L., Peek R.M., Chyou P.H., et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995, 55:2111-2115.
3. Fock K.M., Talley N.J., Fass R., Goh K.L., Katelaris P., Hunt R., et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008, 23:8-22.
4. Fuchs C.S., Mayer R.J. Gastric carcinoma. N Engl J Med 1995, 333:32-41.
5. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
6. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
7. Steeg P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003, 3:55-63.
8. Dormer P., Spitzer E., Frankenberger M., Kremmer E. Erythroid differentiation regulator (EDR), a novel, highly conserved factor I. Induction of haemoglobin synthesis in erythroleukaemic cells. Cytokine 2004, 26:231-242.
9. Dormer P., Spitzer E., Moller W. EDR is a stress-related survival factor from stroma and other tissues acting on early haematopoietic progenitors (E-Mix). Cytokine 2004, 27:47-57.
10. Jung M.K., Park Y., Song S.B., Cheon S.Y., Park S., Houh Y., et al. Erythroid differentiation regulator 1, an interleukin 18-regulated gene, acts as a metastasis suppressor in melanoma. J Invest Dermatol 2011, 131:2096-2104.
11. Kim H.J., Song S.B., Yang Y., Eun Y.S., Cho B.K., Park H.J., et al. Erythroid differentiation regulator 1 (Erdr1) is a proapototic factor in human keratinocytes. Exp Dermatol 2011, 20:920-925.
12. Cho D., Song H., Kim Y.M., Houh D., Hur D.Y., Park H., et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 2000, 60:2703-2709.
13. Jung M.K., Song H.K., Kim K.E., Hur D.Y., Kim T., Bang S., et al. IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway. Immunol Lett 2006, 107:125-130.
14. Kim K.E., Song H., Kim T.S., Yoon D., Kim C.W., Bang S.I., et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 2007, 26:1468-1476.
15. Hitzler I., Sayi A., Kohler E., Engler D.B., Koch K.N., Hardt W.D., et al. Caspase-1 has both proinflammatory and regulatory properties in helicobacter infections, which are differentially mediated by its substrates IL-1beta and IL-18. J Immunol 2012, 188:3594-3602.
16. Kang J.S., Bae S.Y., Kim H.R., Kim Y.S., Kim D.J., Cho B.J., et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis 2009, 30:1987-1996.
17. Sugimoto M., Ohno T., Graham D.Y., Yamaoka Y. Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci 2009, 100:2152-2159.
18. Boyd D. Invasion and metastasis. Cancer Metastasis Rev 1996, 15:77-89.
19. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 1999, 18:15-30.
20. Mao Z., Ma X., Rong Y., Cui L., Wang X., Wu W., et al. Connective tissue growth factor enhances the migration of gastric cancer through downregulation of E-cadherin via the NF-kappaB pathway. Cancer Sci 2011, 102:104-110.
21. Huang C., Jacobson K., Schaller M.D. MAP kinases and cell migration. J Cell Sci 2004, 117:4619-4628.
22. Park H., Byun D., Kim T.S., Kim Y.I., Kang J.S., Hahm E.S., et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett 2001, 79:215-219.
23. Merendino R.A., Gangemi S., Ruello A., Bene A., Losi E., Lonbardo G., et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int J Biol Markers 2001, 16:126-129.
24. Eissa S.A., Zaki S.A., El-Maghraby S.M., Kadry D.Y. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Cancer Inst 2005, 17:51-55.
25. Ye Z.B., Ma T., Li H., Jin X.L., Xu H.M. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 2007, 13:1747-1751.
26. Kim K.E., Song H., Hahm C., Yoon S.Y., Park S., Lee H.R., et al. Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J Immunol 2009, 182:3548-3555.
27. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
28. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012, 4:156-169.
29. Pinho S.S., Oliveira P., Cabral J., Carvalho S., Huntsman D., Gartner F., et al. Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. PLoS One 2012, 7:e33191.
30. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
31. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7:131-142.
32. Cheng J.C., Auersperg N., Leung P.C. EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?. PLoS One 2012, 7:e34071.
33. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172:973-981.
34. Yoon J.H., Kang Y.H., Choi Y.J., Park I.S., Nam S.W., Lee J.Y., et al. Gastrokine 1 functions as a tumor suppressor by inhibition of epithelial-mesenchymal transition in gastric cancers. J Cancer Res Clin Oncol 2011, 137:1697-1704.
35. Chen W., Liang D., Yao C.W., Tao J.L., Chen X.W., Liu H.F. The effect of IL-18 on E-cadherin expression and its possible intracellular pathway in HK-2 cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009, 25:609-611.
36. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999, 79:143-180.
37. Liang B., Wang S., Zhu X.G., Yu Y.X., Cui Z.R., Yu Y.Z. Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol 2005, 11:623-628.
38. Kim J., Kim C., Kim T.S., Bang S.I., Yang Y., Park H., et al. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun 2006, 344:1284-1289.
39. Wang Y., Li Z., Zhang H., Jin H., Sun L., Dong H., et al. HIF-1alpha and HIF-2alpha correlate with migration and invasion in gastric cancer. Cancer Biol Ther 2010, 10:376-382.
40. Chen H.W., Lee J.Y., Huang J.Y., Wang C.C., Chen W.J., Su S.F., et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 2008, 68:7428-7438.
41. Kim H.S., Kim M.H., Jeong M., Hwang Y.S., Lim S.H., Shin B.A., et al. EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res 2004, 24:747-753.
42. Atsumi T., Kato K., Uno K., Iijima K., Koike T., Imatani A., et al. Pathophysiological role of the activation of p38 mitogen-activated protein kinases in poorly differentiated gastric cancer. Pathol Int 2007, 57:635-644.
43. Wang J., Gui Z., Deng L., Sun M., Guo R., Zhang W., et al. c-Met upregulates aquaporin 3 expression in human gastric carcinoma cells via the ERK signalling pathway. Cancer Lett 2012, 319:109-117.